Search Clinical Trials Search
Clinical Trials
× ...
Sort & Filter
Sort by
Specialty

Disease Type/Condition

Age Group


Drug/Medication


162 results found

✔ Specialty: Cancer

Cervix, Liver, Lung, Melanoma, Small Intestine, Stomach, Urinary Bladder

Bioatla, BA3071-001, Ph 1/2, Open-Label, MTD, MUC, NSCLC RP2D, adv solid tumors

Phase 1 Objectives 2.1.1. Primary Objective To define the safety profile, including DLT, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BA3071 when delivered concomitantly with nivolumab, a programmed ...


Melanoma

Modakafusp Alfa (TAK-573) and Pembrolizumab in Advanced or Metastatic Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of an investigational drug called modakafusp alfa in combination with pembrolizumab in patients with metastatic cutaneous melanoma that is unresectable (cannot be ...


Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma: Tafasitamab Plus Lenalidomide in Addition to R-CHOP

This study focuses on individuals who have been recently diagnosed with diffuse large B-cell lymphoma (DLBCL), a cancer of the blood system. Most patients with newly diagnosed DLBCL are treated with the standard therapy called ...


Lung

CSMC, IIT2021-12-Reckamp-Osi105, Ph1, open label, EGFR-mutated NSCLC, Osimertinib and Carotuximab.

Primary Objectives Determine safety and recommended phase 2 dose (RP2D) of combination osimertinib + carotuximab in patients with EGFR mutant NSCLC Secondary Objectives To evaluate the response rate (RR), duration of response (DoR), progression ...


Brain and Nervous System

COG, ACNS1422, Ph2, OL, Newly Dx WNT-Driven Medullo; Reduced Rad + Chemo

Primary Objective: 1. To estimate the progression-free survival (PFS) of children >/= 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor ...